Agenus to Participate at Two Upcoming Conferences in New York City: Jefferies Healthcare and JMP Securities Life Sciences

LEXINGTON, Mass., June 1, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the Company will present at the following conferences to be held in New York City, USA:

  • The 2017 Jefferies Healthcare Conference:
    • Jennifer Buell, Ph.D., Vice President of Research and External Affairs will present on Tuesday, June 6th at 10:30 a.m. EST.
  • The 2017 JMP Securities Life Sciences Conference:
    • Jean-Marie Cuillerot, M.D., Chief Medical Officer will participate in a panel session titled "Immuno-oncology: Checkpoints as Targets" on Wednesday, June 21st at 9 a.m. EST.

Agenus Logo

Webcast Information

The live and archived webcast of the Jefferies presentation will be accessible from the Company's website at www.agenusbio.com/webcast. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay will be available on the Company's website approximately two hours after the call and will remain available for 90 days.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is based in Lexington, MA. For more information, please visit www.agenusbio.com; information that may be important to investors will be routinely posted on our website.

Forward-Looking Statement

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the Company's planned participation in two upcoming conferences. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Contact:  
Agenus Inc.  
Michelle Linn, 781-674-4541  
michelle.linn@agenusbio.com  

SOURCE Agenus Inc.


print email pdf rss